Priavoid is going to start soon after approval of a phase I clinical trial with PRI-002 in April 2018, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2019.

Beitrag aus der Sendung WDR aktuell um 19 Uhr vom 20.03.2018

von WDR akuell